This tissue was procured from a donor determined to be suitable based on the results of screening and testing. Human Cells, Tissues, and Cellular and Tissue-based Products (HCT/P) donor eligibility and placenta suitability, which is based on the results of donor screening at delivery for infectious, malignant, neuro-logical and microbial diseases and for other exposures or social habits, has been determined and documented by TissueTech, Inc.

- A blood specimen, drawn within 7 days of donation, has undergone serological testing by a laboratory registered with the Food and Drug Administration (FDA) to perform donor testing and certified to perform such testing on human specimens in accordance with the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and 42 CFR Part 493, or that has met equivalent requirements as determined by the Centers for Medicare and Medicaid Services (CMS). The donor has been screened for the following infectious diseases and results were non-reactive:
  - HIV-1 & HIV-2 Antibody
  - Hepatitis B Core Antibody (HBcAb)
  - Hepatitis B Virus (HBV, DNA-NAT)
  - Hepatitis C Antibody (HCVAb)
  - Hepatitis B Surface Antigen (HBsAg)
  - Hepatitis C Virus (HCV, R-NAT)
  - HTLV I & II Antibody (HTLV I/II Ab)
  - Hepatitis B Virus (HBV, DNA-NAT)
  - Hepatitis C Virus (HCV, R-NAT)
  - Syphilis (RPR)
  - HTLV I & II Antibody (HTLV I/II Ab)
  - Syphilis (RPR)
  - HIV
  - West Nile Virus (WNV, R-NAT)

- Microbial testing has also been performed on the final product to ensure no growth of aerobic, anaerobic or fungal cultures.
- The cell activity in the tissue has been inactivated using our CryoTek cryopreservation process to reduce the possibility of graft rejection, while retaining the natural biologic properties.
- PROKERA PLUS is stored in a medium of Dulbecco’s Modified Eagle Medium/Glycerol (1:1) containing 20 µg/mL Ciprofloxacin and 1.25 µg/mL Amphotericin B.
- This tissue has been deemed suitable for transplantation based on acceptable screening, serological and microbial test results.
- A Certificate of Compliance regarding the manufacturing, storage, shipping and tracking controls for Bio-Tissue, Inc. products is available upon request.
- PROKERA PLUS is intended for use in eyes in which ocular surface cells are damaged or underlying stroma is inflamed or scarred and best suited for cases of incomplete blinking or eye lid exposure. Acting as a self-retaining biologic corneal bandage, PROKERA PLUS effectively treats superficial corneal surface diseases by suppressing inflammation and related pain, promoting epithelial healing, and avoiding haze.
- Once the packaging is opened, PROKERA PLUS shall either be transplanted or otherwise discarded.
- Do not sterilize or autoclave the product before use.
- Handle PROKERA PLUS with care during insertion.

**Warnings:**
- Do not use on patients with a history of drug reactions to Ciprofloxacin or Amphotericin B.
- As with the use of any human tissue, the possibility of infectious agent transmission cannot be completely eliminated although all screening and microbial testing results for this donor were satisfactory for transplantation.
- It is imperative that the device is stored properly until use. For proper storage instructions, refer to the Storage section.
- If the patient cannot close the eyelid, has an incomplete blink or demonstrates any other signs of exposure, address these clinical issues before or at the same time of placing PROKERA PLUS.
- If the patient cannot tolerate wearing PROKERA PLUS, the device should be removed.

**Contraindications:**
- PROKERA PLUS should not be used in eyes with glaucoma drainage devices or filtering bleb.

**Precautions:**
- Do not use PROKERA PLUS if the device or packaging is damaged – contact Bio-Tissue immediately if there is any abnormality observed (e.g. device, labeling, shipping, missing information, etc.). Refer to the Customer Feedback section for reporting.
- PROKERA PLUS exposed to controlled room temperature (20°C - 25°C) for up to 6 hours may be returned to cold temperature storage in accordance with the Storage section as long as the packaging remains unopened and intact.
- It is imperative that the device is stored properly until use. For proper storage instructions, refer to the Storage section.
- Do not sterileize or autoclave the product before use.
- Handle PROKERA PLUS with care during insertion.

**Location & Temperature**

- **Unopened insulated shipping container**
- **Within the expiration date printed on outer shipping box**

- **Use After Receipt**
- **Within the expiration date printed on product packaging (shelf-life is 2 years from manufacture)**

---

- **-80°C → -4°C (-112°F → -20°F)**
- Example: ultra-low temperature freezer, standard freezer, or standard refrigerator

---

- **See Reverse**
- **Place UDI Label Here**
- **For Canadian Shipments Only**
- **After receipt, store PROKERA PLUS accordingly until time of use.**

**U.S. Patent No. 7,494,802 B2**

**Product Insert**

By the US Food & Drug Administration (FDA), PROKERA PLUS is a Class II medical device cleared by the FDA and a Class IV medical device regulated by Health Canada.
Adverse Events:
The FDA requires that information be supplied to the product manufacturer for mandatory reporting of adverse events. Possible significant adverse events include microbial infection and transmission of viral disease. The doctor is responsible for immediately reporting any adverse event potentially attributable to the use of PROKERA PLUS to Bio-Tissue.

• Upon dissolution of membrane or completion of treatment, remove PROKERA PLUS.
• Do not leave in the eye longer than 30 days.

BT-PI-0018, V2.

1. Apply topical anesthesia
2. Hold the upper eyelid
3. Ask the patient to look down
4. Insert the PROKERA PLUS into the superior fornix
5. Pull lower eyelid down and slide PROKERA PLUS under the lower eyelid
6. Check centration under the slit lamp
7. Apply a tape-tarsorrhaphy over the lid crease (as needed)
   • Apply appropriate medications (as needed)

Recipent Records:
It is the responsibility of the Tissue Dispensing Service, Tissue Distribution Intermediary, and/or End-User Clinician to maintain records for the purpose of tracing tissue post-transplantation. The responsible entity should document the disposition (transplanted or discarded) on the Donor and Recipient Information card (DRI), attach one of the provided PROKERA PLUS tracking labels to the DRI and mail to Bio-Tissue, Inc. Attach the remaining labels in patient and hospital records.

Customer Feedback:
Within the United States: Report any customer feedback, including complaint, error or accident notification promptly to Bio-Tissue at (888) 296-8858 or (305) 412-4430.
Outside of the United States: Report feedback to your local tissue provider.

Complete the following section. Notify via:

Phone: (888) 296-8858 or (305) 412-4430
Fax: (305) 412-4429
Email: Customerfeedback@biotissue.com
Serial Number:
Expiration Date:
Doctor Name:
Facility Name:
Transplant Date:
Diagnosis/Procedure:
Site of Use:
Point of Contact's Name:
Point of Contact's Phone Number:
Date Adverse Event was Reported:
Type of Adverse Event: ☐ Microbial Infection ☐ Transmission of Viral Disease ☐ Other
Describe the Adverse Event:


Manufactured for Bio-Tissue, Inc. by TissueTech, Inc. 8305 NW 27th St, Suite 101, Doral, FL 33122 USA
(888) 296-8858